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Metastasis, the spread of cancer from a primary site to distal sites throughout the body, is 
responsible for 90% of all cancer related deaths.1 Current development of anti-cancer therapeutics 
assumes that drugs targeting tumor growth will also influence metastasis, or that interrupting 
metastasis in the face of overwhelming tumor growth inhibition is not necessary. However, 
proliferation-targeted therapies have little efficacy in targeting or slowing metastatic cellular 
migration and patients succumb to their disease due to advanced metastasis, not due to tumor 
growth. 
Triple negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC) are 
two of the most metastatic cancer subtypes. Currently, there are no targeted therapies available for 
TNBC, but for estrogen receptor (ER), progesterone (PR), and HER2 subtypes, there are highly 
successful therapies available to patients.2 The lack of targeted therapies correlates with the worse 
prognosis associated with TNBC, which has a five-year survival rate of 77% compared to 93% for 
other subtypes of breast cancer.3 For PDAC, the five-year survival rate is 5% for distant disease, 
which has not improved since 2005 and for localized disease, the five-year survival rate is less 
than 30% which is extremely low compared to other cancer types.4 
A new paracrine signaling pathway was discovered that infers a strategy to inhibit cancer 
cell migration by exploiting the synergistic signaling between interleukin 6 (IL-6) and interleukin 
8 (IL-8).5 The discovery of this pathway was facilitated by three-dimensional (3D) models 
specifically designed to track cellular migration in a collagen-rich tumor microenvironment. It is 
important to note this effect is specific to metastatic cancers, making the inhibition of IL-6 and IL-
8 receptors a strategy to slow migration of highly metastatic cancers. 
This study further explores one of the highly metastatic cancer cell lines, MDA-MB-231, 
and the impact of E-cadherin on both proliferation and the invasive phenotype of these cells. We 
also studied the role of IL-6 and IL-8 signaling in PDAC and discovered the combination of anti-
metastatic treatment (tocilizumab and reparixin) with a current monotherapy (gemcitabine) for 
PDAC significantly decreased tumor size and metastasis in a patient derived xenograft mouse 
model. 
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Metastasis is responsible for 90% of cancer related deaths, yet it is not the primary focus of 
anticancer therapies.1 Metastasis is the spread of cancer cells from the primary tumor site to distal 
site(s) via the vascular and lymphatic systems. Proliferation and migration are two key drivers of 
metastasis, but current therapies primarily aim to address the highly proliferative nature of cancer 
cells.   For example, both therapies currently used to treat PDAC, a highly metastatic cancer, are 
cytotoxic and have not been shown to effectively treat metastasis.6 Typically, it is not the size or 
rapid growth of the primary tumor that kills patients, but rather the migration of cells from the 
primary tumor to distal sites.4 Cellular migration is not a consequence of proliferation and should 
be considered a completely separate mechanism. Indeed, pharmacological agents that target 
proliferation do not have an impact on cell migration and can actually make cells more migratory. 
This study explores the mechanisms that govern cell migration and identifies potential therapeutics 
for triple negative breast cancer and pancreatic ductal adenocarcinoma, which are classified as 
highly metastatic. 
1.2 Highly metastatic cancers – triple negative breast cancer and pancreatic ductal 
adenocarcinoma 
In this study, we explore two highly metastatic cancers: triple negative breast cancer (TNBC) 
and pancreatic ductal adenocarcinoma (PDAC). There has been little improvement in outcomes 
for these two diseases because current therapies for these types of cancers cannot effectively target 
metastasis.4 It is assumed that pharmacological agents that can target tumor growth can also target 
metastasis, so many of the current treatments for cancers were primarily tested for their anti-
proliferative capability but were not tested for anti-metastatic capability.4 Therefore, most 
cytotoxic drugs are effective in targeting proliferation but have no effect on preventing 
metastases.4 Currently, there are no targeted therapies available to treat TNBC, but there are highly 
successful therapies available for the other subtypes of breast cancer. 
Due to the lack of specific therapies for TNBC, patients diagnosed with TNBC have a 




year survival rate of 77% compared to other subtypes of breast cancer which have a 93% five-year 
survival rate.3 Patients diagnosed with TNBC also tend to be younger when compared to other 
breast cancer subtypes.3 For PDAC, the five-year survival rate is 5% for distant disease and 30% 
for localized disease, which has not improved much over the past decade. These five-year survival 
rates are some of the lowest among all other types of cancer.4 
1.3 Mechanism of metastasis 
The spread of cancer to multiple sites results in patients having a higher risk of succumbing to 
their disease or a higher risk of recurrence. If a tumor can be isolated and localized to a single site, 
resection surgeries to remove the entirety of the cancer can be performed and fewer cycles of 
chemotherapy would be needed to achieve remission. Localized disease in breast cancer has over 
a 90% chance of 5-year survival and in pancreatic cancer, localized disease is the only stage in 
which the 5-year survival percentage has increased significantly in the last decade.4 
In order to effectively treat highly metastatic cancers, the mechanism of metastasis needs 
to be further elucidated. Depicted in Figure 1, the metastasis cascade is a complex process, with 
multiple steps regulated by genetics, the external environment, cellular signaling, and physical 





 Figure 1: Metastasis cascade. The cartoon depicts the mechanism of metastasis and the various steps 




Once the tumor is vascularized, tumor cells are able to detach from the primary tumor and 
undergo intravasation into the blood vessel, which allows the tumor cells to circulate within the 
vascular system. The detachment of tumor cells from the primary site involves the epithelial to 
mesenchymal transition (EMT), where a reduction in E-cadherin and cytokeratins leads to 
significant changes in both physical and chemical properties of the cells. The adaption to a 
mesenchymal morphology is accompanied by the secretion of matrix metalloproteinases (MMPs), 
which digest and remodel the basement membrane.8,9 After detachment, tumor cells migrate 
through the extracellular matrix (ECM), which is rich in collagen I. The tumor cells are able to 
digest the collagen-rich ECM via the secretion of MMPs, allowing them to migrate through the 
matrix via pseudopodial protrusions regulated by the Arp2/3 complex and focal adhesion 
proteins.10 
Once tumor cells successfully undergo intravasation into the blood vessels, these 
circulating tumor cells can adhere to the blood vessel wall and undergo extravasation, which like 
the process from detachment to intravasation, requires morphological and chemical changes. If the 
tumor cells progress through all of these stages, a secondary tumor can grow at a distal site. 
1.4 Single cell migration through a collagen I matrix 
In a three-dimensional (3D) collagen I matrix, we are able to study cell migratory phenotypes 
and how they degrade the collagen matrix. Collagen is the most abundant fibrous protein within 
the interstitial ECM and supports chemotaxis and migration.11 During single cell migration, tumor 
cells are exposed to the collagen rich extracellular matrix, which the cells can remodel to be stiffer 
and more suitable for their growth. MMPs are secreted and activated by tumor cells to further 
remodel the ECM and basement membrane and initiate the release of ECM-embedded growth 
factors.11 The degradation and manipulation of the ECM is closely correlated with enhanced 
cellular migration through the matrix. 
The migration of tumor cells through a collagen-rich ECM is modulated by the generation 
of pseudopodial protrusions, which allow tumor cells to stiffen and remodel the collagen matrix. 
The protrusions are regulated by focal adhesion components, which are composed of clustered 
integrins that connect the cellular actin network to the ECM fibers.10 It has been demonstrated that 
protrusions generated in 3D environments are both multigenerational and dendritic. Protrusions 




regulated by FAK, talin, and p130Cas. Studies have shown that the protrusions that stem from 
mother protrusions (referred to as daughter protrusions) are regulated by the Arp2/3 complex as 
well as N-WASP, WAVE1, cortactin, Cdc42, and VASP. It is the rate of generation of these 
daughter protrusions, not the length, that is closely associated and can predict cell speed in 3D 
collagen I matrices.10 
 In this study, we utilize a 3D cell culture system that closely simulates the collagen-rich 
ECM of tumor tissue. This 3D system provides a comprehensive and rapid method to analyze 
tumor cell migration and proliferation. Cells suspended in this 3D matrix are easily visualized by 
phase contrast microscopy and easily treated with various reagents, which allows for extensive 
screening of biological responses to growth factors and chemical agents. 
1.5 Motivation for the study 
Current therapies for TNBC and PDAC have mechanisms of action that are anti-
proliferative, yet metastasis is responsible for the vast majority of deaths in these types of cancer. 
Previous studies have demonstrated new insights into the mechanisms that govern metastasis by 
elucidating a relationship between local tumor cell density and migration. These insights have 
helped researchers establish new therapeutic targets that solely target metastasis through the 
inhibition of IL-6 and IL-8. With this basis, two projects were conducted to further explore the 
migratory phenotypes of these highly metastatic cancers.  TNBC cells, MDA-MB-23, were studied 
in a much more compact high-cell density environment with a specific focus on the impact of E-
cadherin on migratory phenotype shifts and invasion. Another highly metastatic cancer – 
pancreatic ductal adenocarcinoma – was also studied to demonstrate that the synergistic signaling 




2 Migratory phenotypes 
During detachment, tumor cells adopt a migratory phenotype that allows them to move 
through the ECM.12 Traditionally, cellular migration has been studied on two-dimensional, flat 
surfaces, which do not recapitulate the in vivo environment. The use of three-dimensional collagen 
I matrices allows us to simulate the collagen rich environment these tumor cells migrate through 
in vivo. The generation and use of a realistic model to study cellular migration has provided new 
insights into the dynamics of cellular migration.10,13,14 
Many factors can impact a cell’s migratory phenotype, including environmental factors and 
genetic factors.13,14 We explored the impact of both environmental and genetic factors on cell 
migratory phenotypes in a 3D system. When tumor cells initially break away from the primary 
tumor during the detachment stage, they are in a high cell density environment. When the cells 
leave the ECM and undergo intravasation, their environment changes drastically and their 
migratory phenotype shifts, suggesting cell density has an impact on the migratory phenotype of 
cancer cells. 
From a clinical data perspective, certain genes are associated with worse prognoses. For 
TNBC, elevated expression of E-cadherin is associated with a lower recurrence free survival rate 
when compared to patients with a lower expression of E-cadherin.15 The impact of both an 
environmental factor (cell density) and a genetic factor (high expression of E-cadherin) has been 
explored to better understand how to prevent these enhanced migratory and invasive phenotypes 
seen in both PDAC and TNBC. 
2.1 Mechanism of cell-density dependent migration in TNBC 
The impact of cell density on the migratory patterns in TNBC cell line MDA-MB-231 
has been explored by Jayatilaka, et al. 5 Under high cell-density conditions, MDA-MB-231 cells 
show migratory phenotypic shifts in speed and persistence which is a direct result of the protrusion 
frequency (shown in Figure S8).5  Cell-density also impacts the amount of secreted IL-6 and IL-8, 















Understanding how cell density affects 
the migratory phenotype of metastatic cancers 
requires an understanding of the mechanism behind 
the phenotypic shift. The IL-6 and IL-8 signaling 
pathway leads to enhanced cell motility via the 









Secreted IL-6 and IL-8 are sensed by their respective receptors via a paracrine pathway and 
initiate a cascade that leads to the enhanced generation of the Arp2/3 complex, which is directly 
linked to protrusions, as shown in the figure above.5 As previously mentioned, the Arp2/3 
complex, along with focal adhesion proteins, regulates pseudopodial protrusions. The rate of 
protrusions directly correlates with enhanced cell speed; therefore, the IL-6 and IL-8 receptors 
Figure 2: Cell-density effect on IL-6 and IL-8 secretions. Concentration of IL-6 
(A)  and IL-8 (B) in cell supernatant was evaluated using an ELISA assay. IL-6 and 
IL-8 concentration in the supernatant increased with cell density. 5 
Figure 3: Cascade initiated by IL-6 and IL-8. The cascade initiated by the binding of IL-6 
and IL-8 to their respective receptors initiates a cascade that leads to the generation of the 





prove to be excellent targets for therapeutic agents to decrease the generation of the Arp2/3 
complex and by extension, slow the rate of protrusions and migration.5,14  
 
2.2 Targeting IL-6 and IL-8 to slow metastasis 
The paracrine signaling activated via IL-6 and IL-8 receptors was studied extensively by 
Jayatilaka, et al. 5. The intermediate pathway shown in Figure 3 was mapped out using RNA-
sequencing as well as qPCR, protein, and inhibitor studies. Inhibitors of IL-6 (Tocilizumab, 
Genentech), IL-8 (Reparixin, Med Chem Express), JAK2 (AG-490, Santa Cruz Biotechnology), 
STAT3 (S3I-201, Santa Cruz Biotechnology), and Arp2/3 complex (CK 666, Sigma Aldrich) were 
all used to map out the pathway depicted in Figure 3. It was determined that inhibiting IL-6 and 
IL-8 (with Tocilizumab and Reparixin) was most effective in slowing the migration of tumor cells 
in a 3D collagen I matrix. 
2.2.1 Tocilizumab and reparixin – mechanism of action 
Tocilizumab is the first FDA approved agent that prevents IL-6 from binding to its receptor. 
It is a monoclonal antibody that competitively binds to the IL-6 molecule’s receptor and therefore 
prevents IL-6R signal transduction to inflammatory mediators that summon B and T cells.16 Based 
on the results from clinical trials for the treatment of arthritis, it has been determined as a safe 
alternative to methotrexate (the current standard of treatment) and also safe to be used in 
combination with methotrexate to reduce inflammatory response. Both of these points are 
important to note, when considering using Tocilizumab in combination with other agents. 
Reparixin is an CXCR1/2 antagonist that acts as an IL-8 receptor inhibitor and is currently 
in clinical trials to treat breast cancer. CXCL8 (IL-8) binds to CXC R1/2, as a crucial member of 
leukocyte recruitment.17 Reparixin is a non-competitive allosteric blocker of CXCR1/2 but has 
higher efficacy in inhibiting CXCR1.17 The mechanism of 












2.2.2 Impact of tocilizumab and reparixin combination therapy on metastatic burden 
The combination of tocilizumab and reparixin reduced metastatic burden without affecting 
tumor growth in an in vivo study with MDA-MB-231 conducted by Jayatilaka, et al. 5  This novel 
combination therapy reduced metastasis to the organs most frequently affected by metastasis in 
breast cancer, shown in Figure 5.5 The combination was the only treatment that reduced metastasis 









Figure 4: Mechanism of action for tocilizumab and reparixin. Tocilizumab and 
reparixin inhibit IL-6 and IL-8, respectively, by binding to the receptors.5 
(E) 






The discovery of this novel pathway gives insight into the mechanism by which cancer 
cells metastasize from a localized tumor site, laying the groundwork for future studies of highly 
metastatic cancer types. 
2.3 Impact of E-cadherin on migratory phenotype  
2.3.1 E-cadherin: the tumor suppressor gene 
E-cadherin is a cell-cell adhesion molecule that plays an important role in epithelial cell 
behavior, tissue formation, and some research shows it plays a role in suppressing cancer.18 More 
generally, E-cadherin is part of the cadherin family, a large category of transmembrane 
glycoproteins that mediate specific cell-cell adhesion via Ca2+ dependence. There are five major 
subfamilies of cadherins, but E-cadherin belongs to the ‘classical’ or type I subfamily and is one 
of the most extensively studied classical cadherins.18 E-cadherin is specifically associated with 
three catenins (alpha, beta, and p120) which link E-cadherin to the actin cytoskeleton.19 An 




with the help of 
intracellular catenins, 
among other proteins. 
 
Figure 5:  Impact of tocilizumab and reparixin on tumor volume and metastatic burden. The impact of 
tocilizumab and reparixin alone in comparison to their combination is shown in a-d. (A) shows that tumor volume 
was not impacted by treatment with tocilizumab, reparixin, or the combination therapy when compared to the 
control. (B), (C), and (D) show the metastatic burden to the lungs, liver, and lymph nodes is significantly decreased 
with a combination treatment of both tocilizumab and reparixin. Metastatic burden was measured by conducting 
qPCR of the H2K gene. (E) H&E staining of excised lungs further validating the metastatic burden to the lungs is 







Experimental evidence has shown that the loss of E-cadherin correlates with increased 
metastasis and invasion, as it is thought that loss of E-cadherin promotes metastatic dissemination 
by disrupting intercellular contacts.19 As studied by Onder, et al. 19, the loss of E-cadherin promotes 
the disaggregation of cancer cells because it disrupts cell-cell adhesion within in a tumor. It has 
also been shown that the suppression of E-cadherin function leads to mesenchymal morphology 
and increased cellular migration and invasion.20 
2.3.2 Paradox of E-cadherin 
Based on an in vitro study conducted at Harvard Medical School, CDH1, the gene that 
encodes E-cadherin protein, was determined to be a tumor suppressor gene (TSG), not an 
oncogene.21  Figure 7 shows the genes analyzed in the study, where red boxes denote TSGs and 
green boxes denote oncogenes. 
Figure 6: Schematic overview of E-cadherin-catenin complex. Shows the E-cadherin-
catenin complex (CCC) at the junction between two neighboring epithelial cells, showing the 























Previous studies have questioned if E-cadherin is truly a tumor suppressor gene, suggesting 
that previously thought TSG may actually be an oncogene, promoting a more invasive migratory 
phenotype.15 We further explored the impact of E-cadherin expression in a clinical setting, shown 
in Figure 8. 
Figure 7: Schematic of the genes analyzed. Shows the analyzed tumor suppressor genes 
and oncogenes in their respective pathways and how they come together to impact cell 
function. The blue box highlights the cell-cell adhesion pathway, where CDH1 is shown 




The data in Figure 8 shows patients with a high expression of E-cadherin have a significantly lower 
relapse free survival probability when compared to patients with low expression of E-cadherin. 
However, loss of E-cadherin has been shown to promote metastasis and invasion. Since there is a 
large disconnect between experimental data and clinical data, we further explored the role of E-
cadherin in triple negative breast cancer cells. 
2.3.3 Impact of E-cadherin on TNBC 
The paradoxical role of E-cadherin has been previously explored, as it is still not well 
understood how E-cadherin over-expression results in a worse prognosis in a clinical setting. 
Previous studies show the impact of E-cadherin overexpression in the same triple negative breast 
cancer cell line studied by Jayatilaka et al, MDA-MB-231. Utilizing a novel, double-layered 
spheroid model, the in vitro results, shown in Figure 9, correlated with the clinical data shown in 





Figure 8: Recurrence probability for patients expressing E-cadherin. (A) shows the correlation between 
high expression E-cadherin (red) compared to low expression of E-cadherin (black) for all subtypes and 
stages of breast cancer. (B) shows the correlation between high and low expression of E-cadherin for TNBC 




further test this result, we conducted an in vivo study to test the impact of E-cadherin 
overexpression in mice injected with MDA-MB-231 into the mammary fat pad of NSG mice. The 
results are shown in Figure 10, confirming 
the correlation of E- cadherin with 










Figure 9: Normalized spheroid volume over time. Shows over-expression of E-cadherin 
correlates with faster spheroid progression when compared to lower-expressing E-cadherin 
spheroids. (Ong, et al. JHU, unpublished data). 
Figure 10: Tumor volume over time for in vivo study. Tumor volume was measured weekly in mice 
injected with MDA-MB-231 WT and MDA-MB-231 + E-cadherin. Tumors generated from cells over-
expressing E-cadherin progressed much faster when compared to low-expressing E-cadherin tumors 




Based on Figures 9 and 10, the double layered spheroid model is able to recapitulate the in vivo 
correlation of E-cadherin. The mouse study conducted was primarily to demonstrate the increased 
proliferation that is correlated with overexpression of E-cadherin 
3 A novel spheroid model to study migratory phenotypes in TNBC 
The paradox of E-cadherin needs to be further explored as research data that suggests E-
cadherin is a tumor suppressor gene conflicts with clinical data that shows higher expression of E-
cadherin correlates with lower recurrence free survival. To further study the impact E-cadherin has 
on proliferation and tumor progression, a new spheroid model was developed that strived to 
recapitulate the tumor microenvironment more accurately. 
3.1 Double-layered spheroid model (3DLTS) 
A novel, double layered spheroid system was developed to better study cancer cells in vitro. 
Current methods of spheroid generation use mechanical manipulation to form cells coated in either 
matrigel or collagen into a compact spherical shape.22 However, a novel method of double-coated 
spheroids gives a more realistic model by including a “basement” membrane composed of matrigel 
and a collagen I layer to mimic the stromal layer surrounding tumors. In comparison to organoid 
models, this system utilizes collagen as the stroma layer surrounding the inner spheroid that is 
mixed with matrigel. Most organoid models utilize matrigel to simulate the ECM, not collagen.23  
However, the utilization of collagen to simulate the tumor stroma (ECM) allows for better drug 
penetration compared to matrigel.24 This main difference allows for a more high-throughput drug 
screening application. 
Previous studies have shown that cells over-expressing E-cadherin invade the collagen 
coating, which simulates the tumor stroma, in half the time when compared to cells not expressing 















As shown in Figure 11, the MDA-MB-231 + E-cadherin 3DLTS invaded the tumor stroma 
in 9 days, compared to the MDA-MB-231 WT 3DLTS, which took 19 days to completely invade 
the tumor stroma. This supports the in vivo mouse model results shown in Figure 9. With this basis, 
further studies were conducted to understand how the over-expression of E-cadherin was 
impacting the cells migratory and invasive phenotypes. 
3.2 How E-cadherin affects invasive phenotype 
As shown in the above sections, both in vitro and in vivo studies showed over-expression of E-
cadherin correlates with faster spheroid progression, which is one of the defining characteristics 
of metastatic cells. We also observed that over-expression of E-cadherin induces a change in 
invasive phenotype of the cells as they migrate from the inner spheroid into the collagen layer. As 
shown in Figure 12a, MDA-MB-231 WT 3DLTS exhibit a collective cell migration from the inner 
spheroid into the collagen layer, where a few cells are migrating through the collagen layer together 
and invade further into the collagen layer. In Figure 12b, MDA-MB-231+E-cadherin 3DLTS 










To understand how E-cadherin impacts the behavior of TNBC cells, three different 
signaling pathways were studied at the mRNA level to see if overexpression of E-cadherin has any 
downstream impacts on gene expression. The MAPKinase, WNT, and HIPPO pathways were 
Figure 11: Spheroid progression differences seen in over-expression of E-cadherin. Comparison of 
3DLTS progression in MDA-WT and MDA+E-cadherin at day 9, demonstrating that MDA+E-cad leads 
to increased tumor progression. (Ong et al, JHU, unpublished results). 
Figure 12: Invasive phenotype induced by E-cadherin over-expression. (A) MDA-MB-231 
WT 3DLTS exhibits a collective cell invasion from the inner spheroid into the tumor stroma. (B) 
MDA-MB-231+E-cadherin exhibits a ‘connected’ cell migration from the inner spheroid into the 





selected based on previous research that links E-cadherin loss or gain of expression to having 
impacts on intermediate proteins within these complex pathways. 
3.2.1 MAPKinase signaling pathway and the role of ERK, JNK, p38 
The MAPKinase pathway (shown in Figure S2) consists of a three-tiered kinase cascade 
that includes a MAP kinase kinase kinase (MAP3K or MEKK), a MAP kinase kinase (MAP2K or 
MEK), and a MAP kinase (MAPK).25  In our studies, we focused on the genes that encode the 
MEK and MAPK protein complexes as well as downstream proteins from those cascades. ERK is 
the most well-studied pathway within MAPKinase singaling.25 Activated Raf (b-Raf is the 
strongest MEK kinase) activates MEK1 and MEK2 by phosphorylating serines 218 and 222, which 
then activate ERK1/2 via phosphorylation of tyrosine 204 and 187, respectively. Once activated, 
ERK can phosphorylate numerous cytoplasmic and nuclear targets, which in turn leads to ERK 
having the ability to regulate processes such as proliferation, differentiation, survival, migration, 
angiogenesis, and chromatin remodeling.25 
The JNK pathway is considered a stress activated pathway within MAPKinase signaling. 
Activation of JNK requires the dual phosphorylation of tyrosine and threonine residues at a 
distinctive TPY motif, which is catalyzed by MEK4 and MEK7.25 JNK also has the ability to 
translocate from the cytoplasm to the nucleus and phosphorylate a number of transcription factors, 
including AFT-2 and STAT-3. In response to stresses, JNK interacts with p53, a well-studied 
mutation in many cancer types. 
The p38 pathway is also considered a stress activated pathway within MAPKinase 
signaling and can also translocate from cytoplasm to the nucleus. p38 is activated by environmental 
stresses and inflammatory cytokines. Activated p38 is involved in the regulation of apoptosis, cell 
cycle progression, growth, and differentiation.25 
3.2.2 WNT signaling pathway and the role of beta-catenin 
Early studies of WNT suggest that it can be linked to the malignant transformation of 
mouse mammary tissue. Recent studies have demonstrated WNT signaling is a central mechanism 
in cancer cell biology.26 We chose to study the genes that encode the proteins involved in the main 
scaffold of the WNT canonical pathway (shown in Figure S3) because it causes an accumulation 
of beta-catenin, which is known to exclusively form a complex with E-cadherin. Beta-catenin is 




E-cadherin has on the WNT pathway, we focused on the proteins surrounding beta-catenin as well 
as downstream complexes that regulate the cell cycle. 
3.2.3 HIPPO signaling pathway and the role of YAP/TAZ 
The HIPPO pathway (shown in Figure S3) controls organ size and tissue growth during 
development, regeneration, and cancer.27 TAZ and YAP are two key components of the HIPPO 
signaling pathway and have been studied in depth for their role in cancer-related HIPPO signaling. 
Genetic variations in the HIPPO pathway in TNBC have been linked to over-expression of TAZ 
(J Zhang). TAZ and YAP hyper-activation leads to abnormal cell proliferation, a hallmark of 
cancer and metastasis.4,7,27  It has been shown that overexpression of TAZ/YAP can promote cell 
survival both in vivo and in vitro. In cancer cell lines, the overexpression of TAZ/YAP results in 
resistance to apoptosis. The WNT signaling pathway is known to functionally interact with the 
HIPPO pathway in many ways, but more specifically for our purposes, TAZ has been shown to 
interact with WNT signaling by interacting with Dvl1 in the cytoplasm and YAP or TAZ can 
interact with beta-catenin and keep it in the cytoplasm.27,28 With these interactions in mind, we 
chose to study parts of the HIPPO pathway that lead to the transcription of genes that result in pro-
proliferation as well as the interactions with beta-catenin in the WNT signaling pathway. 
3.3 RT-PCR to evaluate signaling pathways 
To evaluate the selected pathways, quantitative real time PCR was used to evaluate the relative 
gene expression of selected genes in MDA-MB-231 WT and MDA-MB-231 + E-cadherin, 














In Figure 13, the relative gene expression for CDH1, the gene that encodes E-cadherin 
protein, is shown to be significantly upregulated in MDA-MB-231 + E-cadherin when compared 
to MDA-MB-231 WT. This confirmation shows successful transduction of E-cadherin into the cell 
line and preservation of E-cadherin over-expression in 3DLTS system. 
3.3.1 PCR Results- MAPKinase signaling pathway 
The relative gene expression for the MAPKinase signaling pathway is shown below in 
Figure 14 (A-C). Our results show that there is significant upregulation of FOS, MAP2K1, 
MAPK1, MAPK14, MAPK3, MAPK8, and MAPK9. These genes encode proteins involved in the 
ERK, JNK, and p38 cascades within the MAPKinase signaling pathway. 
 
Figure 13: Relative expression of CDH1 in 2D and 3D conditions. Shows the relative expression of CDH1, 
the gene that encodes E-cadherin in MDA-MB-231+E-cadherin (red) compared to MDA-MB-231 WT (blue) 
in both 2D condition (A) and 3DLTS (B). (N = 3) 
Figure 14: Relative Gene Expression of MAPKinase Signaling. Relative gene expression of MDA-MB-231 +E-cadherin 
compared to MDA-MB-231 WT. Upregulation is considered above a 2-fold increase. (A) shows upregulation of the ERK 
cascade, (B) shows upregulation of the JNK complex, and (C) shows upregulation of the p38 complex. (N = 4) 
(A) (B) (C) 
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The ERK cascade was significantly upregulated both upstream and downstream from the 
ERK1/2 complex, suggesting that the impact of E-cadherin on the MAPKinase pathway can be 
reversed with the inhibition of ERK1/2. 
3.3.2 PCR Results- WNT signaling pathway 
The relative gene expression for the WNT signaling pathway is shown in Figure 15. Our 
results show there is a significant upregulation of APC, CCND1, CSNK1A1, CSNK2A1, 
CTNNB1, GSK3Beta, HDAC1, LEF1. 
 
 As expected, we observed a significant upregulation of beta-catenin in MDA-MB-231+E-
cadherin, but we also saw upregulation of many genes that encode proteins surrounding the beta-
catenin protein complex as well as genes that encode proteins downstream of beta-catenin. The 
upregulation of HDAC1 is an important observation, as the upregulation of this gene that encodes 
the enzyme HDAC1, closely interacts with beta-catenin to regulate LEF-1 transition from a 
transcriptional repressor to an activator of downstream genes.31 
3.3.3 PCR Results- HIPPO signaling pathway 
The relative gene expression for the HIPPO signaling pathway is shown in Figure 16. Our 
results show significant upregulation of LATS1, SERPINE1, and TEAD1. As mentioned 
previously, the key genes for assessing the involvement of HIPPO signaling are YAP/TAZ, which 
we observed to be unchanged in MDA-MB-231+E-cadherin. 
Figure 15: Relative gene expression of WNT signaling pathway. Relative gene expression of MDA-MB-231 
+ E-cadherin compared to MDA-MB-231 WT. Upregulation is considered above a 2-fold increase. (A) shows 
upregulation of GSK3Beta. (B) shows upregulation of genes that encode proteins that interact with beta-
catenin. (C) shows upregulation of downstream products of beta-catenin complex. (N=4) 
 















The upregulation of LATS1 results in downstream impacts, such as the upregulation of 
TEAD1 and SERPINE1, which encodes Pai-1, a pro-proliferative protein. The unchanged 
expression of YAP/TAZ suggest the HIPPO signaling pathway is not significantly impacted by 
the overexpression of E-cadherin, since YAP/TAZ have the most widespread impact on 
downstream products of the HIPPO signaling pathway, shown in Figure S3. These results were 
used to design the drug inhibitor studies that provided insight into which gene/protein can be 
targeted for phenotype reversal. 
3.4 Exploring ERK at the protein level 
To further study the MAPKinase pathway, western blot studies were conducted to observe 
if there was a significant difference in the phosphorylation of ERK1/2 in MDA-MB-231+E-
cadherin when compared to MDA-MB-231 WT. Since mRNA expression level of genes that 
encode proteins does not always translate to the protein expression, we conducted a western blot 
to confirm that the upregulation we observed in the gene expression of the ERK cascade is indeed 
present at the protein level. Shown in Figure 17, MDA-MB-231+E-cadherin has a significantly 
higher level of phosphorylated and total ERK1/2 when compared to WT. 
Figure 16: Relative gene expression of HIPPO signaling pathway. Relative gene expression of MDA-MB-
231 + E-cadherin compared to MDA-MB-231 WT. Upregulation is considered above a 2-fold increase. (A) 
shows upregulation of an inhibitor of YAP/TAZ complex -LATS1. (B) shows upregulation a downstream 





Based on the Figure 17, there is a significantly higher amount of total ERK in MDA-MB-
231+E-cadherin than present in MDA-MB-231 WT. This demonstrates that the mRNA levels of 
the genes that encode ERK1/2 correlate with the observed protein levels in the 3DLTS system. 
3.5 Drug inhibitor studies using 3DLTS 
The development of the 3DLTS model has allowed for high-throughput drug screening 
experiments that can test numerous inhibitors, at numerous concentrations in a side-by-side 
experiment. This experimental design was implemented to study the effect of inhibitors on tumor 
growth rate and migratory phenotypes in both MDA-MB-231 WT and MDA-MB-213+E-
cadherin. 
3.5.1 Drug screening with MAPKinase and WNT inhibitors 
 Inhibitors for several target genes in the MAPKinase and WNT signaling pathways were 
selected to target various genes selected for characterization of the three pathways. In Table 1, the 
inhibitors selected are listed with their target genes. 
Table 1: Inhibitors used for drug screening. 
Inhibitor (given code) Target (Pathway) 
SP600125 (MI1) JNK (MAPKinase) 
BI-78D3 (MI2) JNK (MAPKinase) 
PD0325901(MI4) MEK (MAPKinase) 
SB203580 (MI5) p38(MAPKinase) 
Figure 17: Protein Expression of ERK and Phosphorylated-ERK are higher in MDA-MB-231 + E-cadherin 
3DLTS. Western blot images (A) and intensity graphs (B) of MDA-MB-231+E-cadherin compared to MDA-MB-
231 WT. This confirms that over-expression of E-cadherin leads upregulation of genes in the ERK cascade 




Vemurafenib (MI6) B-Raf (MAPKinase) 
MK-2206 (MI7) AKT (MAPKinase) 
IWR-1-endo (WI1) Axin2-Beta-catenin interaction (WNT) 
LY317615 (WI2) PKC (WNT) 
CHIR-98014 (WI3) GSK3beta (WNT) 
 
A preliminary screening was done with all inhibitors and compared to MDA-MB-231+E-
cadherin control to select the inhibitors to be studied more extensively. In Figure 18, MDA-MB-
231+E-cadherin 3DLTS were treated with 10 µM for the screening. Only the inhibitors that 
showed to revert MDA-MB-231+E-cadherin back to the MDA-MB-231 WT migratory phenotype 













The data in Figure 18 was then quantified to better understand the impact the inhibitors had 
on the inner spheroid progression and outer stroma volume preservation. Both outer and inner 
tumor volume was then calculated for each inhibitor screened using a method of analysis 
previously outlined by Ong et al (Figure S1). 
Figure 18: Visualization of inhibitor impact on 3DLTS (MDA-MB-231 + E-cadherin). Figure above 
shows the impact of each inhibitor at a concentration of 10uM (listed in Table 1) on the 3DLTS. Red 
boxes indicate the inhibitors that were able to preserve tumor stroma volume and prevent inner spheroid 
volume from progressing as quickly. Blue box is an untreated control for comparison purposes. 
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Based on the data shown in Figure 19, MI1, MI4, and WI3 inhibitors were selected for 
further screening. The chosen concentration of 10uM is extremely high, so another screening was 
done with MI1, MI4, and WI3 at 1uM concentration. The results in Figure S2 show that only MI4
was effective at a lower concentration at both preventing the inner tumor volume from progressing 
as quickly and preserving the stroma volume from decreasing as quickly.
This data was then compared to the mRNA relative gene expression data presented in the 
previous section. MI4, an MEK inhibitor, proved to be the most effective inhibitor in both 
preventing inner tumor volume growth and maintaining the volume of the collagen layer (stroma). 
Further studies were conducted to determine the optimal concentration of MI4 to revert the 
migratory phenotype induced by E-cadherin back to the WT migratory phenotype. 
3.5.2 MEK inhibitor impact on invasive phenotype 
MI4, an MEK inhibitor, proved to be the most effective at suppressing the impact of E-
cadherin overexpression on the migratory phenotype.  MI4 (PD0325901) has been shown to 
significantly reduce the growth of papillary thyroid carcinoma cells both in vitro and in vivo and 
is considered a second generation MEK1/2 inhibitor that prevents the phosphorylation of ERK1/2 
by inhibiting MEK activation.29 PD0325901 was previously tested for efficacy in treating 
melanoma and solid tumors, but the clinical trial was terminated due to severe side effects. 
PD0325901 is currently in the beginning stages of clinical trial recruitment for colorectal cancer 
and is in two active clinical trials for KRAS mutant non-small cell lung cancer and 
neurofibromatosis type 1.30 
Figure 19: 10uM inhibitor screening with MDA-MB-231+E-cadherin 3DLTS. (A) shows ratio of the inner spheroid 
volume measurements from day 7 compared to day 1. (B) shows outer spheroid volume measurements from day 7 
compared to day 1. Blue bars indicate statistical significance with a p<0.05. Inhibitors were selected for further 
screening if these volume ratios measured 1±0.5 (N=4) 
(A) (B) 
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In Figure 20, the IC50 of MI4 is displayed as a log scale of the various drug concentrations 
tested. The results were used to determine the optimal concentration of the inhibitor for both inner 
and outer volume optimal effect. 
As shown earlier in Figure 12, over-expression of E-cadherin also alters the invasive 
phenotype of the cells as they invade the tumor stroma (collagen layer). In Figure 21, the impact 







MEK inhibitor (PD0325091) not only slowed the enhanced growth of MDA-MB-231+E-
cadherin 3DLTS, but also reverted the invasive phenotype back to that of the MDA-MB-231 WT 
3DLTS. This finding shows that the inhibition of MEK not only is effective at slowing the higher 
proliferation rate of MDA-MB-231+E-cadherin but also is effective at preventing the more 
Figure 20: IC50 graphs of MI4 for both the inner spheroid volume. (A) and the outer stroma volume (B), volumes 
are a ratio of day 7 measurements to day 2 measurements. Results indicate the log IC50 of the inhibitor on the inner 
volume is 1.041 and for the outer volume, it is 2.088. Both of these values were used to determine optimal 
concentration of inhibitor for treatment of MDA-MB-231+E-cadherin 3DLTS.  
Figure 21: Reversion of invasive phenotype with MEK inhibitor treatment. (A) shows an untreated MDA-
MB-231+E-cadherin 3DLTS control for comparison to (B) MDA-MB-231 + E-cadherin 3DLTS treated with 
MEK inhibitor. Images are zoomed into highlight the invasion of the cells from the inner spheroid into the 






invasive and collective migration that is shown in Figure 21a. The mRNA gene expression analysis 
shows a significant upregulation of the genes that encode MEK1/2- MAP2K1/2 (expression levels 
shown in Figure 14a. However, an overexpression of a gene does not necessarily mean more 
protein is being encoded so western blot studies were conducted to confirm the increased 
phosphorylation of ERK1/2 (encoded by MAPK1/3) by MEK1/2 (encoded by MAP2K1/2). 
3.6 Future directions 
 Based on these findings, more studies need to be conducted to demonstrate that MI4 
(PD0325091) successfully decreases the phosphorylation of ERK1/2 in E-cadherin over-
expressing cells. This will give the final confirmation that the upregulation of MEK1/2 
phosphorylation of ERK1/2 in MDA-MB-231+E-cadherin is the cause for the migratory 
phenotype shift and higher proliferation rate seen in the 3DLTS model of these cell line subtypes. 
Both gene expression and proteins analyses will be conducted on treated MDA-MB-231+E-
cadherin to confirm the inhibition of MEK1/2 by MI4 results in decreased phosphorylation of 
ERK1/2. 
4 Pancreatic ductal adenocarcinoma and IL-6/IL-8 signaling 
4.1 Background 
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of 8% for all stages 
combined, but for the distant metastasis stage, which accounts for 52% of patients at the time of 
diagnosis, the five-year survival rate is 3%.2 Unfortunately, there has been little improvement in 
the past decade to improve these statistics, likely because the standard of care therapies for PDAC 
are anti-proliferative and do not target metastasis.4 It is difficult to diagnose PDAC at early stages 
because the symptoms are generalized to abdominal pain and weight loss, which could result from 
any number of diseases. Unfortunately, cancer is usually one of the last considerations with such 





4.2 Standard of care therapies 
Gemcitabine is the first-line therapy offered to patients with good performance status, as it 
has been shown to be almost five times more effective in achieving a clinical benefit response 
when compared to 5-fluorouracil.6 The primary mechanism of action for Gemcitabine is to inhibit 
DNA synthesis by preventing chain elongation.31 When taken up by cells, gemcitabine is 
phosphorylated three times in the cell cytoplasm, resulting in the formation of gemcitabine 
triphosphate (dFdCTP). As shown in Figure 22, dFdCTP is incorporated into the DNA chain 
followed by a single deoxynucleotide. The dFdCTP initiates masked chain termination which 
prevents DNA polymerases from completing. 
The secondary mechanism of action is to inhibit the enzymes associated with 
deoxynucleotides. Shown in Figure 23, dFdCTP directly inhibits the enzymes, whereas dFdCDP 
indirectly inhibits the enzymes by covalently binding to the active sites which prevents 
ribonucleotide reductase activation.31 This inhibition decreases dCTP activity and increases dFdC 
phosphorylation. 
 
Figure 22: Gemcitabine - Primary mechanism of action. The replacement of one of the deoxynucleotides with 
dFdCTP prevents DNA synthesis by interrupting DNA polymerase formation. 31 
Figure 23: Gemcitabine- secondary mechanism of action. The dFdCDP molecules covalently bond to the active 




Gemcitabine also activates p38 mitogen-activated protein kinase (MAPK) and induces 
cellular stress in tumor cells only.31 Cellular stress leads to apoptosis in the tumor cells, but normal 
cells are generally not affected by this mechanism of action. 
5-Fluorouracil (5-FU) is the second-line of therapies offered to patients before combination 
therapies will be suggested, as these combination therapies with drugs such as Abraxane and 
FOLFIRINOX (a combination of irinotecan, oxaliplatin, fluorouracil, and leucovorin), are highly 
toxic and positive response to these therapies often results in the occurrence of adverse side 
effects.6 5-FU is an antimetabolite drug that inhibits thymidylate synthase (TS) and disrupts RNA 
synthesis. It is an analogue of uracil, so it is able to rapidly enter the cell using the same facilitated 
transport mechanism as uracil.32 5-FU is converted into its active metabolites as shown in Figure 
24: fluorodeoxyuridine-monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), and 
fluorouridine triphosphate (FUTP). The rate limiting enzyme in the conversion of 5-FU to its active 











metabolite FUTP is incorporated into RNA and disrupts normal RNA processing and function. 
The incorporation of FUTP into RNA can result in toxicity at multiple levels, including the 
processing of pre-rRNA to mature rRNA, the post-transcriptional modificaition of tRNAs, and 
both the completion and activation of snRNA-protein complexes.32 The metabolite FdUMP binds 
to the nucleotide-binding site of TS, which forms a stable ternary complex and blocks the binding 
Figure 24: 5-Fluoruoracil- Mechanism of action. Metabolism of 5-FU resulting in DNA and 




of the normal substrate deoxyuridine monophosphate (dUMP) to TS. By blocking the binding of 
dUMP to its binding site on TS, FdUMP effectively inhibits dTMP synthesis, shown in Figure 25. 
TS is an important enzyme that produces the only de novo source of thymidylate, which is 
necessary for DNA replication and repair. TS catalyzes the reductive methylation of dUMP to 









Both standard of care therapies initiate DNA damage in the cells via different mechanisms 
of action; however, the toxicity of these two therapies limits the possibilities of combination 
therapies with other chemotherapy drugs. The combinations that have been attempted so far have 
resulted in either higher toxicity levels in patients or significant increase in other adverse side 
effects of the drugs.32 A different approach is needed to improve efficacy of treatment without 
increasing toxicity. 
4.3 Impact of cell-density on secreted IL-6/IL-8 in PDAC 
To further test the impact of IL-6 and IL-8 signaling in PDAC, we conducted a secretomic 
analysis using an ELISA assay. A cell line derived from a pancreatic liver metastasis, Capan-1, 
was used for the experiment. Cells were embedded into 3D collagen I gels at varying densities and 
incubated for 24 hours with fresh media. The cell supernatant was harvested and used to conduct 
the ELISA assays to quantify the amount of secreted IL-6 and IL-8. In Figure 26, the concentration 
of IL-6 and IL-8 increases with cell-density for Capan-1.  
Figure 25: 5-FU-mechanism of action. The inhibition of TS activity results in DNA 
damage by preventing the production of the only de novo source of thymidylate for DNA 










With these results, we hypothesized that the same phenomenon observed in MDA-MB-231 
TNBC cells is also applicable in PDAC cells. With this basis, we designed an in vivo study using 
a PDX mouse model and proposed a combination therapy to improve efficacy of treatment for 
PDAC. 
4.4 In vivo study – patient derived xenograft (PDX) mouse model 
Based on the in vitro data, we suspected that we could prevent metastasis by inhibiting IL-
6 and IL-8 with the tocilizumab and reparixin combination. Since previous combination therapies 
failed due to high toxicity and increased adverse side effects, we hypothesized that the combination 
of gemcitabine with the anti-metastatic combination would be an effective and safer way to treat 
PDAC. Using a subcutaneous PDX mouse model, we tested the efficacy of our proposed triple 
combination therapy of tocilizumab, reparixin, and gemcitabine. 
4.4.1 Experimental design of in vivo study 
In designing this in vivo study, we wanted to compare the final effect of just the anti-
metastasis drugs (T+R), gemcitabine alone (G), and the triple combination (T+R+G) on both tumor 
growth and metastasis. The ½ T+R+G dose was included in the study to see if the triple 
combination would be effective enough to allow for a lower dose of each component and thus 
reduced risk. The study was broken into 5 total groups outlined in Table 2. Each condition group 
contained 5 mice with the exception in the ½ T+R+G group, which had 4 mice. 
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Figure 26: Concentration of secreted IL-6 and IL-8 increase with cell density in Capan-1.  (A) ELISA assay 
results for IL-6 show secreted IL-6 concentration increases with cell density (N=3). (B) ELISA assay results for 




























4.4.2 Results of in vivo study 
Over the course of the study, we observed decreased tumor volume in the proposed 
combination therapy group. As shown in Figure 27, the tumor volume for the T+R+G condition 
was significantly smaller when compared to the other conditions. As suspected, the T+R treatment 
had no impact on the tumor volume. The T+R+G group had a decreased tumor volume that was 













Tumor volume measurements were taken on the last day of the study (day 60) and mice 
were sacrificed the following day. A side by side comparison between tumor volume and tumor 










 The tumor weight showed statistical significance only in the T+R+G combination group 
when compared to the control. This data shows that the combination therapy is effective in 
improving the efficacy of treatment and unexpectedly also improving the anti-proliferative effect 
of gemcitabine. In Figure 29, visualization of the consistency between tumor size shows that the 
T+R+G combination resulted in tumor size 
consistency, which was unexpected. This result 
suggests that there is a synergistic relationship 




Figure 27: Comparison of tumor growth for each condition. Subcutaneous tumor growth over the 60-day study. 
Tumor volume was calculated using (x,y) measurements from VWR digital calipers (±0.0004mm). Tumors were 
categorized as spheres or ellipses by calculating the difference between x and y. If x-y < 1mm, the tumor volume was 
calculated using the volume formula for a sphere. If x-y > 1mm, the tumor volume was calculated using the volume 
formula for an ellipse. 
Figure 28: Final tumor measurements for PDX mouse model. (A) Weight of excised tumors indicates only 
T+R+G treatment resulted in statistically significant reduced tumor growth. (B) Final volume measurements, 











To determine if metastatic burden was decreased in the combination therapy, DNA was 
extracted from harvested organs and analyzed for the expression of H2K, a marker of human 
genomic material. Our data shows that the combination of T+R+G was effective in preventing 
metastasis to the lungs and the liver, which is the primary site of metastases in PDAC. The 
expression of H2K in the T+R+G was comparable to the T+R group, which is expected. The other 














The data from the PDX subcutaneous mouse model demonstrates that a combination of 
tocilizumab and reparixin to target metastasis can be used with an anti-proliferative drug to 
Figure 29: Excised tumors for each treatment group. Visualization of tumor size consistency in 
all the treatment groups suggests the T+R+G combination therapy improves the anti-proliferative 
effect of gemcitabine. Scale bar (in bottom right of figure) is ½ inch.  

























































Figure 30: Metastatic burden to lung and liver is reduced in T+R+G combination therapy group. 
(A) shows the relative expression of H2K in the lungs, a marker of human genomic material, is reduced 
in both the T+R and T+R+G groups. (B) shows the relative expression of H2K in the liver is reduced in 




increase overall efficacy of treatment. Further studies will be conducted using an orthotopic model 
to improve relevancy and include the other monotherapy, 5-FU, currently used for treatment of 
PDAC. 
4.5 Future studies 
Based on these findings, another in vivo study will be conducted in immune-competent 
mice with an orthotopic tumor implantation to improve accuracy of the metastatic spread. The 
subcutaneous model in immune-suppressed mice has shown efficacy of our proposed combination 
therapy, but further validation is needed to make progress towards a clinical trial. More in vitro 
studies will be conducted to better understand the paracrine pathway that enables cells to sense IL-
6 and IL-8 secretions and initiate the intracellular cascade that promotes enhanced migratory 
phenotypes. 
5 Exploring unconventional metastasis 
As mentioned previously, metastasis is defined as the spread of cancer from the primary 
tumor site through the circulatory or lymphatic systems to a secondary site. This mechanism of 
metastasis has been studied extensively, allowing researchers to study the various signaling 
pathways and proteins that are involved in this process. However, this is not the only mechanism 
by which tumor cells metastasize to a secondary site. Cancers arising in the peritoneal cavity can 
bypass the process of intravasation and extravasation by disseminating into the peritoneal fluid 
and migrating to a secondary site. Both ovarian and pancreatic cancer cells can metastasize via 
this mechanism, which is not well understood. We wanted to explore this other mechanism of 
metastasis, since peritoneal cancers are some of the deadliest. 
5.1 Metastasis and the omentum 
In ovarian cancer, the omentum is the most common site of metastasis, and other cancers 
arising in the peritoneal cavity often metastasize to the omentum as well.33 The omentum is a 
complex fatty membrane that lies on top of the abdominal organs, functioning as the “policeman 
of the abdomen” due to its immune response when pathogens are present in the peritoneal cavity.34 
The mechanism by which cancer cells metastasize to omentum is not well understood, but 




bypassing the mechanism outlined earlier that involves the circulatory or lymphatic systems.35-37 
Lengyel et al have studied the impact of adipocytes and mesothelial cells on ovarian cancer cell 
behavior, but their models lack some important ECM components that we suspect are necessary 
to map the mechanism by which cancer cells are able to metastasize within the peritoneal cavity 
and why the omentum is one of the most common sites of metastases for abdominal cancers. With 
this basis, we have begun to explore the mechanism of metastasis utilizing a novel co-culture 
system that includes many of the native and specific components. 
 
5.2 Development of a novel co-culture system 
 Previous studies conducted by Lengyel et al used a co-culture system of mesothelial 
cells, which are present on the surface of the omentum, and adipocytes, which comprise the inner 
fatty layers. However, the models used in previous studies look at cell invasion in 3D matrices 
and quantified invasion by fluorescently labeling ovarian cancer cells and quantifying the 
number of cells that successfully migrated to the mesothelial layer. Other models quantified 
proliferation and adhesion to various ECM variations, but none have studied how the omentum 
affects the migratory phenotypes of these cells.35-37 
 With this basis, we proposed a novel co-culture system that will allow us to study the 
impact the omentum has on the migratory phenotypes of ovarian and pancreatic cancer cells. 
This novel system recapitulates the ECM utilizing a type I collagen matrix and fresh human 









 By embedding a 
piece of fresh human omentum into a collagen I matrix, we can co-culture cancer cells with the 
Figure 31: Omentum co-culture system. Proposed 3D system to study the impact 
of omentum on cancer cell migration and phenotypes. Omentum tissue and cells 




tissue and track how the cells morphology and migratory patterns change in the presence of all 
the components of the omentum. As mentioned previously, the omentum is an extremely 
complex tissue, and keeping the tissue intact allows us to simulate a physiologically relevant 
ECM to track cancer cell migration and phenotypic shifts.  
5.3 Future studies 
 We have conducted preliminary studies with this novel co-culture system and observed a 
surprising phenomenon. We will continue to explore the mechanism of metastasis within the 
peritoneal cavity, with an initial focus on the impact of the omentum on ovarian and pancreatic 
cancer cell migratory phenotypes.  
6 Materials and methods 
6.1 TNBC and E-cadherin project 
Cell culture 
Human breast carcinoma MDA-MB-231 cells (ATCC) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Sigma Aldrich) supplemented with 10% (v/v) fetal bovine serum (FBS, 
Corning) and 1% Penicillin-Streptomycin (Corning). The cells were maintained in at 37°C and 5% 
CO2 in a humidified incubator during cell culture and during live-cell microscopy studies. 
 
Lentiviral expression constructs18 
The lentiviral vector of enhanced green fluorescent protein (EGFP; pCS-CG) was purchased from 
Addgene (Cambridge, MA). The lentiviral vector of lifeact-EGFP and E-cadherin-EGFP were 
generated from pCS-CG. The sequence of lifeact peptide or full-length E-cadherin was cloned 
upstream of EGFP between the Nhe1 and Age 1 sites of pCS-CG to generate EGFP-fused protein. 
The aE-catenin shRNA vector was generated as described before. Briefly, the sequence 50-
GGACCTGCTTTCG GAGTACAT-30 targeting aE-catenin was cloned downstream of the H1 
promoter between the MluI and ClaI sites in pLVTHM lentiviral vector (Addgene). 
 




A second-generation lentivirus was produced as described previously (11). Briefly, MDA-MB-
231 cells (ATCC) were transiently co-transfected with three plasmids (lentiviral vector, DR 8.91, 
and pMDG-VSVG) using the standard calcium phosphate precipitation method. After 22–24 h of 
transfection, the medium was replaced with fresh medium. The lentiviral particles were harvested 
24 h later, immediately filtered through 0.45 mm filter (Millipore) to remove cells debris, and then 
stored at 80°C. For transduction, 1*105 cells in a 35-mm culture dish were repeatedly transduced 
with lentivirus with 8 mg/ml polybrene to reach high transduction (>80%) to generate MDA-MB-
231 + E-cadherin. 
 
 
Double-layered spheroid model 
A double layered spheroid model was generated with matrigel (Corning) and rat tail type I 
(Corning). Cells were trypsinized, pelleted, and re-suspended in matrigel such that the final 
concentration of cells was 50,000 per 0.6 uL. Oil columns were prepared in 10 uL pipette tips 
without a filter/barrier. First, 10uL of media was aspirated and tips were placed back into the box. 
Then, 40uL of sterile biological grade mineral oil (Sigma Aldrich) was added to the top of the 
pipette tip. To generate the first layer, 0.6 uL of the matrigel/cell mixture is pipette into each 
prepared oil column. Incubate at 37°C for 1 hr. 
After 1 hr incubation, the matrigel layered sphere is formed. With a cut 200uL pipette tip, spheroids 
were taken out of the oil column and put into an Eppendorf tube of media. The spheroids should 
sink to the bottom of the Eppendorf. To generate the second layer, a 2mg/mL collagen I gel was 
mixed as previously described by Frayley et al.16 Matrigel layered spheroids were carefully 
dropped into the collagen gel mixture. Using a cut tip, 6 uL of collagen mixture + spheroid was 
aspirated and dropped into the oil column from earlier. The second layer was incubated for 1 hr at 
37°C. After the second layer set, the spheroids were washed again in media and then plate in a 96 
well round-bottom dish and suspended in media. 
 
Quantifying double-layered spheroid volume 
Inner and outer layers were manually traced using NIS Elements software to generate a radius 




formula: 𝑉𝑉 = 4
3
𝜋𝜋𝑟𝑟3.  To calculate the volume of the collagen layer (stroma), the inner volume was 
subtracted from the total volume.  
 
mRNA extraction 
Spheroids were generated and then incubated for 24hrs in fresh media. After 24hrs, spheroids were 
harvested and washed 3x in DPBS (Corning). To isolate mRNA,TriZol reagent (Invitrogen) was 
added to the spheroids and then vortexed until completely dissolved. Direct-zol Mini Prep kit 
(Zymo research) reagents and protocol were used to finish the RNA extraction process.  
 
 
cDNA synthesis and qPCR 
cDNA was synthesized using Bio-Rad cDNA iScript kit following the protocol to make 1000ng/uL 
of cDNA for a total reaction volume of 20uL. qPCR was conducted with  iTaq-SYBR Green (Bio-
Rad) using the Bio-Rad CFX CFX384 Touch Real-Time PCR Detection System. Primers were 
obtained from Integrated DNA Technologies. A complete list of primers and sequences is included 
in Supplementary Table 1. 
 
Inhibitor studies 
Inhibitor studies were conducted using 3DLTS system described above. Experiments were carried 
out for 1 week and imaged every day using phase microscopy. NIS Elements was used to manually 
trace the inner and outer layers of the spheroids to generate a radius measurement for calculations. 
Volume calculations were used to track the size of both the inner sphere (cells) and the outer sphere 
(stroma). Inhibitors were obtained from Sellechem and fresh or conditioned media was added on 
the day the spheroids were generated and not changed during the week-long experiment. 
 
Protein extraction and assay (western blot) 
A clear sample buffer containing SDS was used to lyse 10-15 spheroids. Samples were sonicated 
to manually break up the gel layers and dissolve the collagen and matrigel. Samples were then 
heated at 100°C for 5 minutes to completely denature the protein. Protein samples were stored in 




with the instructed amount of beta mercaptoethanol and added in a one-to-one ratio to the protein 
samples. Bio-rad mini protean gels with a 4-15% gradient were used for gel electrophoresis. 
Transblot Turbo packs from Bio-rad were used for transfer from gel to PVDF membrane. 
Antibodies were purchased from Cell Signaling Technology and recommended dilutions for the 
primary and secondary antibodies were used in blocking. Blots were imaged using Bio-Rad imager 
and bands were quantified using ImageJ.  
 
 
6.2 PDAC and IL-6/IL-8 signaling project 
Cell culture 
Human pancreatic ductal adenocarcinoma cells Panc-1 (ATCC) were cultured in DMEM (Sigma 
Aldrich) supplemented with 10% (v/v) FBS (Corning) and 1% Penicillin-Streptomycin (Corning). 
Human pancreatic ductal adenocarcinoma cells Capan-1 (ATCC) were cultured in IMDM (ATCC) 
supplemented with 20% FBS (Corning). The cells were maintained in at 37°C and 5% CO2 in a 
humidified incubator during cell culture and during live-cell microscopy studies. 
 
3D collagen I matrix for single cell migration studies 
PDAC cell lines Panc-1 and Capan-1 were embedded in 2mg/mL type I collagen gel as described 
previously by Fraley et al.16 Cell suspensions containing 5,000 to 75,000 cells in a 1:1 (v/v) ratio 
of cell culture media and reconstitution buffer were mixed with soluble rat-tail type I collagen 
(Corning) to obtain a final collagen concentration of 2mg/mL. After adding the appropriate 
collagen volume, a calculated volume 1M NaOH was added quickly to have a final solution pH of 
approximately 7. The cell-suspension gel mixture was added to 24-well coverslip-bottom cell 
culture dish on a plate heater set to 37°C for approximately 5 minutes and then transferred to an 
incubator maintained at 37°C to allow for polymerization. Fresh media was added 1 h after gels 






PDAC cell lines were seeded in high and low densities in 2mg/mL collagen I matrices in a 6-well 
plate coverslip-bottom cell culture dish. High density wells received conditioned medium or 
control medium and then were harvested after 24-hour incubation. Collagenase (Corning) was 
prepared in DPBS (Corning) for a final concentration of 2mg/mL. An equal volume of collagenase 
was added to the total collagen volume for each condition into conical tubes and incubated for 1 h 
in a humidified incubator at 37°C with 5% CO2. After collagen was dissolved, the cells were 
pelleted via centrifugation and re-suspended in 2-3mL of DPBS to remove any residual 
collagenase and media serum. Cells were pelleted again via centrifugation and DPBS was removed 
to begin the RNA extraction process. mRNA was extracted from the cell pellet using TriZol 
(Invitrogen). Direct-zol RNA mini-prep kit (Zymo Research) using the supplied reagents. 
Absorbance values of 260/280 (acceptable range: 2.2-1.7) and 260/230 (acceptable range: below 
2.3) were used for quality control purposes. 
 
Secretomic analysis (ELISA) 
PDAC cells were seeded in 2mg/mL collagen I gels at varying cell densities and media was 
harvested after 24 hours of incubation and centrifuged. ELISA kits were obtained from R&D 
systems and experiment was carried out using supplied reagents and protocol. 
 
PDX mouse model 
Studies using 6-8 week old NSG (NOD SCID Gamma) mice were carried out according to 
protocols approved by the Johns Hopkins University Animal Care and Use Committee in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals. All mice were housed 
at a temperature of 25°C under a 12 hr dark/light cycle. NSG mice were obtained from Jackson 
Laboratories and were implanted with tumor cells subcutaneously by Jackson Laboratories 
before arrival at the mouse facilities at the Johns Hopkins University. Tocilizumab and saline 
were obtained from Genentech, Reparixin was obtained from Med Chem Express, and 
Gemcitabine was obtained from Sagent. Injections began 11 days after tumor implantation. The 
control group mice were injected with 100 uL saline. Treatment groups were injected with 100 uL 
gemcitabine (30 mg/kg), 100 uL of tocilizumab and reparixin combination (both 30mg/kg), 200 




and gemcitabine (all 15 mg/kg). Mice were injected every three days for approximately 9 weeks 
(61 days). Tumors were measured in two dimensions (x and y) with calipers on the same day as 
injections and mice were weighed once a week. Tumors were categorized as spheres or ellipses by 
calculating the difference between x and y. If x-y < 1mm, the tumor volume was calculated using 
the volume formula for a sphere. If x-y > 1mm, the tumor volume was calculated using the volume 
formula for an ellipse. Mice were sacrificed using isoflurane and cervical dislocation. Primary 
tumors were excised and weighed. The liver, lungs, lymph nodes, spleen, pancreas, kidneys, brain 
were also harvested for mRNA/qPCR studies. 
Processing of harvested mouse tissues 
All tissues were fixed in formalin to be sectioned and stained. The primary tumors were not stained 
but sectioned for future studies. All tissues except the lymph nodes were H&E stained, and lymph 
nodes were stained with pan cytokeratin. RNA and protein were extracted from primary tumors 
using All-Prep RNA/Protein Kit (Qiagen) using the supplied reagents and protocol. DNA was 
extracted from all other organs using Invitrogen PureLink Genomic DNA Mini-kit (Thermo 
Fischer Scientific). To test for metastatic burden, qPCR was run to test for the expression of the 
H2K gene, which is a marker of human genomic material.  
 
Gene sequences for qPCR 
Beta actin was chosen as the housekeeping gene for normalization.. Primer mix included forward 
and reverse of both human and mouse DNA primers for B-actin. 
 
B-actin PDAC Fwd AGATCAAGATCATTGCTCCTCCT 
B-actin PDAC Rvs ACGCAGCTCAGTAACAGTCC 
B-actin mouse 1 Fwd ATGAGCTGCCTGACGGCCAGGTCATC 
B-actin mouse 1 Rvs TGGTACCACCAGACAGCACTGTGTTG 
 
H2K Fwd CCAGTTCATTCACATCATCAG 






The mean values of data presented ± SEM were calculated and plotted using 
GraphPad Prism software (GraphPad Software). One-way ANOVA test and T-
TEST were used to determine statistical significance between data sets. Statistical 
significance presented on the graphs uses the Michelin grade scale: 
**** P<0.001 
*** P <0.01 
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Figure S1:Spheroid measurement graphic. Red annotations show how the 




As outlined in the methods section, the spheroid volume measurements were calculated by 






Figure S2: MAPKinase signaling pathway. Simplified schematic of the individual cascades 
within the complex MAPKinase pathway. Boxes contain the protein name and the gene name 

























Figure S3: WNT signaling pathway. Simplified schematic of the WNT canonical pathway. Boxes contain the 
protein name and the gene name that encodes the protein in parentheses. 
Figure S4: HIPPO signaling pathway. Simplified schematic of the HIPPO signaling 



























Figure S6: Proliferation fold increase for MDA-MB-231 WT and MDA-MB-231 +E-cadherin in both 2D and 
3DLTS.  In 2D condition, there is no difference between the fold increase in the cells over-expressing E-cadherin, 
but in the 3DLTS system, over-expression of E-cadherin results higher fold increase per day when compared to 
lower-expressing E-cadherin cells. 
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Figure S5: 10uM and 1uM inhibitor screening. Inhibitor screening of the inhibitors selected after the initial 10uM 
screening experiment. Only MI4 was able to maintain the tumor stroma volume and prevent the inner spheroid volume 
from progressing as quickly when treated with the lower concentration.  





















































Figure S7: Metastatic burden analysis on spleen and kidneys. Expression of H2K was evaluated to 





















Supplementary Table 1: 
MAPK Pathway Gene Primer List  
Primer Sequence 
AKT1 FWD AGCGACGTGGCTATTGTGAAG 
AKT1 RVS GCCATCATTCTTGAGGAGGAAGT 
ATF2 FWD AATTGAGGAGCCTTCTGTTGTAG 
ATF2 RVS CATCACTGGTAGTAGACTCTGGG 
DAXX FWD GATACCTTCCCTGACTATGGGG 
DAXX RVS GTAACCTGATGCCCACATCTC 
ELK1 FWD CTGCCTCCTAGCATTCACTTC 
ELK1 RVS GCTGCCACTGGATGGAAACT 
FOS FWD CCGGGGATAGCCTCTCTTACT 
FOS RVS CCAGGTCCGTGCAGAAGTC 
GREB1 FWD ATGGGAAATTCTTACGCTGGAC 
GREB1 RVS CACTCGGCTACCACCTTCT 
JUN FWD TCCAAGTGCCGAAAAAGGAAG 
JUN RVS CGAGTTCTGAGCTTTCAAGGT 
JUND FWD TCATCATCCAGTCCAACGGG 
JUND RVS TTCTGCTTGTGTAAATCCTCCAG 
Figure S8: Cell density dependent speed in MDA-MB-231. As cell density 
is increased, cell speed increases. There is a point at which the effect plateaus, 






MAP2K1 FWD CAATGGCGGTGTGGTGTTC 
MAP2K1 RVS GATTGCGGGTTTGATCTCCAG 
MAP2K2 FWD AGGTCCTGCACGAATGCAA 
MAP2K2 RVS CGTCCATGTGTTCCATGCAA 
MAP2K3 FWD GAGGGAGACGTGTGGATCTG 
MAP2K3 RVS CCGCACGATAGACACAGCAAT 
MAP2K4 FWD TGCAGGGTAAACGCAAAGCA 
MAP2K4 RVS CTCCTGTAGGATTGGGATTCAGA 
MAP2K5 FWD CCGGACCCTCTCAACACAG 
MAP2K5 RVS ATGACCAAGAGTGTCCCGATA 
MAP2K6 FWD AAACGGCTACTGATGGATTTGG 
MAP2K6 RVS CAGTGCGCCATAAAAGGTGAC 
MAPK1 FWD TCACACAGGGTTCCTGACAGA 
MAPK1 RVS ATGCAGCCTACAGACCAAATATC 
MAPK10 FWD CAGATGGAATTAGACCATGAGCG 
MAPK10 RVS TCAATGTGCAATCAGACTTGACT 
MAPK12 FWD AGTGGCTTTTACCGCCAGG 
MAPK12 RVS GACTGGAAGGGCCGATACAG 
MAPK13 FWD TGAGCCGACCCTTTCAGTC 
MAPK13 RVS AGCCCAATGACGTTCTCATGC 
MAPK14 FWD TCAGTCCATCATTCATGCGAAA 
MAPK14 RVS AACGTCCAACAGACCAATCAC 
MAPK3 FWD CTACACGCAGTTGCAGTACAT 
MAPK3 RVS CAGCAGGATCTGGATCTCCC 
MAPK8 FWD TCTGGTATGATCCTTCTGAAGCA 
MAPK8 RVS TCCTCCAAGTCCATAACTTCCTT 
MAPK9 FWD GAAACTAAGCCGTCCTTTTCAGA 
MAPK9 RVS TCCAGCTCCATGTGAATAACCT 
MAX FWD CAATCTGCGGCTGACAAACG 
MAX RVS GCACTTGACCTCGCCTTCT 
TRAF2 FWD CCTTCCCAGATAATGCTGCCC 
TRAF2 RVS GCTCTCGTATTCTTTCAGGGTC 
 
 
Supplementary Table 2: 
 
WNT Pathway Gene Primer List  
Primer Sequence 
APC FWD AAGCATGAAACCGGCTCACAT 
APC RVS CATTCGTGTAGTTGAACCCTGA 

































AXIN1 RVS CCGTCGAAGTCTCACCTTTAATG 
BTRC FWD TGCCCAAGCAACGGAAACT 
BTRC RVS GCCCATGTTGGTAATGACACA 
CCND1 FWD GCTGCGAAGTGGAAACCATC 
CCND1 RVS CCTCCTTCTGCACACATTTGAA 
CSNK1A1 FWD AGTGGCAGTGAAGCTAGAATCT 
CSNK1A1 RVS CGCCCAATACCCATTAGGAAGTT 
CSNK2A1 FWD CGAGTTGCTTCCCGATACTTC 
CSNK2A1 RVS ACTTGCCAGCATACAACCCAA 
CTBP1 FWD CGACCCTTACTTGTCGGATGG 
CTBP1 RVS TTGACGGTGAAGTCGTTGATG 
CTNNB1 FWD AGCTTCCAGACACGCTATCAT 
CTNNB1 RVS CGGTACAACGAGCTGTTTCTAC 
DVL1 FWD GAGGGTGCTCACTCGGATG 
DVL1 RVS GTGCCTGTCTCGTTGTCCA 
FZD1 FWD ATCTTCTTGTCCGGCTGTTACA 
FZD1 RVS GTCCTCGGCGAACTTGTCATT 
GSK3B FWD GGCAGCATGAAAGTTAGCAGA 
GSK3B RVS GGCGACCAGTTCTCCTGAATC 
HDAC1 FWD CTACTACGACGGGGATGTTGG 
HDAC1 RVS GAGTCATGCGGATTCGGTGAG 
LEF1 FWD AGAACACCCCGATGACGGA 
LEF1 RVS GGCATCATTATGTACCCGGAAT 
NLK FWD CCAACCTCCACACATTGACTATT 
NLK RVS ACTTTGACATGATCTGAGCTGAG 
PPARD FWD GCCTCTATCGTCAACAAGGAC 
PPARD RVS GCAATGAATAGGGCCAGGTC 
PPP2CA FWD GTTCGTTACCGTGAACGCATC 
PPP2CA RVS TGGCGAGAGACCACCATGT 
WIF1 FWD TCTCCAAACACCTCAAAATGCT 
WIF1 RVS GACACTCGCAGATGCGTCT 
WNT1 FWD CGATGGTGGGGTATTGTGAAC 
WNT1 RVS CCGGATTTTGGCGTATCAGAC 
WNT11 FWD GGAGTCGGCCTTCGTGTATG 
WNT11 RVS GCCCGTAGCTGAGGTTGTC 
WNT5A FWD ATTCTTGGTGGTCGCTAGGTA 




Supplementary Table 3: 
HIPPO Pathway Gene Primer List 
Lable Name Sequence 
Hs1 PUMA delta FWD GCCAGATTTGTGAGACAAGAGG 
Hs2 PUMA delta RVS CAGGCACCTAATTGGGCTC 
Hs3 CTGF FWD CAGCATGGACGTTCGTCTG 
Hs4 CTGF RVS AACCACGGTTTGGTCCTTGG 
Hs5 GLI2 FWD CTGCCTCCGAGAAGCAAGAAG 
Hs6 GLI2 RVS GCATGGAATGGTGGCAAGAG 
Hs7 AREG FWD GTGGTGCTGTCGCTCTTGATA 
Hs8 AREG RVS CCCCAGAAAATGGTTCACGCT 
Hs9 BIRC5 FWD AGGACCACCGCATCTCTACAT 
Hs10 BIRC5 RVS AAGTCTGGCTCGTTCTCAGTG 
Hs11 AFP FWD CTTTGGGCTGCTCGCTATGA 
Hs12 AFP RVS GCATGTTGATTTAACAAGCTGCT 
Hs13 ITGB2 FWD AAGTGACGCTTTACCTGCGAC 
Hs14 ITGB2 RVS AAGCATGGAGTAGGAGAGGTC 
Hs15 SERPINE1 FWD TAGACCGATTATTGACCGACCT 
Hs16 SERPINE1 RVS GTTTGCCACGAGAATCAAATCC 
Hs17 AXIN2 FWD CAACACCAGGCGGAACGAA 
Hs18 AXIN2 RVS GCCCAATAAGGAGTGTAAGGACT 
Hs19 NKD1 FWD GGGAAACTTCACTCCAAGCC 
Hs20 NKD1 RVS CTCCCGATCCACTCCTCGAT 
Hs21 SOX2 FWD TACAGCATGTCCTACTCGCAG 
Hs22 SOX2 RVS GAGGAAGAGGTAACCACAGGG 
Hs23 SNAI2 FWD CGAACTGGACACACATACAGTG 
Hs24 SNAI2 RVS CTGAGGATCTCTGGTTGTGGT 
Hs25 BIRC2 FWD AGCACGATCTTGTCAGATTGG 
Hs26 BIRC2 RVS GGCGGGGAAAGTTGAATATGTA 
Hs27 YAP1 FWD TAGCCCTGCGTAGCCAGTTA 
Hs28 YAP1 RVS TCATGCTTAGTCCACTGTCTGT 
Hs29 TAZ FWD CACCGTGTCCAATCACCAGTC 
Hs30 TAZ RVS TCCAACGCATCAACTTCAGGT 
Hs31 TEAD1 FWD ATGGAAAGGATGAGTGACTCTGC 
Hs32 TEAD1 RVS TCCCACATGGTGGATAGATAGC 
Hs33 LATS1 FWD AAACCAGGGAATGTGCAGCAA 
Hs34 LATS1 RVS CATGCCTCTGAGGAACTAAGGA 
Hs35 MST1 FWD AAGCCGCAGTTCACGTTTAC 
Hs36 MST1 RVS GGGTCCATCGTGTAGCACC 




Hs38 CTNNA1 RVS GTTGCCTCGCTTCACAGAAGA 
Hs39 CDH1 FWD CGAGAGCTACACGTTCACGG 
Hs40 CDH1 RVS GGGTGTCGAGGGAAAAATAGG 
Hs41 YWHAZ FWD CCTGCATGAAGTCTGTAACTGAG 
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